The Manila Times

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that ...
Ophthalmology Times

Harrow receives FDA IND clearance for phase 3 trial of TRIESENCE after cataract surgery

FDA IND clearance enables a phase 3 program evaluating TRIESENCE for postoperative ocular inflammation and pain following cataract surgery, aiming to broaden on-label use beyond current intraocular ...
Nasdaq

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the execution of a five-year strategic supply and development (“SSD”) ...